Introduction
============

Diabetes mellitus is one of the most challenging chronic diseases ([@b18-dmso-1-033]; [@b23-dmso-1-033]) associated with significant morbidity and mortality ([@b3-dmso-1-033]; [@b28-dmso-1-033]). In order to avoid or delay microvascular complications, a strict metabolic control of blood glucose is recommended ([@b36-dmso-1-033]; [@b21-dmso-1-033]; [@b37-dmso-1-033]). Measure of glycosylated hemoglobin A (HbA~1c~) is used to evaluate glycemia control. For the majority of diabetics, glycemia control is considered attained when HbA~1c~ levels are less than 7% ([@b12-dmso-1-033]; [@b2-dmso-1-033]).

Many patients do not achieve optimal glycemia control ([@b30-dmso-1-033]; [@b29-dmso-1-033]). Longer diabetes duration and presence of complications are both associated with poor glycemia control ([@b4-dmso-1-033]; [@b29-dmso-1-033]; [@b38-dmso-1-033]; [@b5-dmso-1-033]; [@b17-dmso-1-033]; [@b19-dmso-1-033]; [@b27-dmso-1-033]; [@b32-dmso-1-033]). The majority of diabetic patients have at least one comorbid chronic condition ([@b4-dmso-1-033]; [@b5-dmso-1-033]; [@b19-dmso-1-033]), a problem that may also have an impact on glycemia control. Indeed, competing situations may occur in the treatment of patients ([@b27-dmso-1-033]), and the presence of several symptomatic comorbidities may influence patients' self management ([@b17-dmso-1-033]). However, reports on the relationship between comorbidity and glycemia control are conflicting. In some cases, evidence suggests that comorbidity is associated with lower glycemia control ([@b39-dmso-1-033]; [@b38-dmso-1-033]; [@b32-dmso-1-033]), whereas other data argue against any association ([@b6-dmso-1-033]). These conflicting results may be explained by the use of different methods to measure comorbidity. In two studies, the Charlson comorbidity index was used ([@b39-dmso-1-033]; [@b38-dmso-1-033]). However, this index was originally developed to predict mortality risk and includes a limited list of diseases. Another study used the chronic disease score (CDS) ([@b6-dmso-1-033]), a comorbidity measure based on sex, age, and drugs prescribed to the patient. The remaining study took into account a limited number of conditions traditionally known as diabetes complications ([@b32-dmso-1-033]).

Uncontrolled diabetes may result in complications such as nephropathy, renal failure, hypertension, congestive heart failure and coronary disease ([@b1-dmso-1-033]). Therefore, any study on a possible association between glycemia control and comorbidity, in which the measure of comorbidity would only include such chronic conditions would be biased towards finding an association. Furthermore, in addition to the type of comorbidity, its severity may either cause poor glycemia control or be a consequence of it.

Since many diabetic patients have comorbidity ([@b4-dmso-1-033]; [@b5-dmso-1-033]; [@b19-dmso-1-033]), it is important to determine if comorbidity increases the difficulty to manage the disease and to achieve good glycemia control. Therefore, the aim of the present study was to evaluate the relationship between diabetes control and comorbidity using a comprehensive comorbidity index in a primary care setting.

Methods
=======

We performed a retrospective descriptive study based on chart review at the family medicine unit (FMU) of the Centre de Santé et de Services Sociaux de Chicoutimi, Quebec, Canada. The study was approved by the institutional ethics committee.

Using the electronic laboratory database available, we performed a random selection of patients with type 2 diabetes who had at least two measurements of HbA~1c~ levels between January 1st, 2004 and September 1st, 2006. Patients diagnosed with diabetes less than a year before the last measurement of HbA~1c~ and those under the care of the researchers involved in this study were excluded.

Three trained nurses extracted data from patients' paper charts. Data extracted from the charts included sex, age, the last two measures of HbA~1c~, the presence or absence of diabetes-related complications, time elapsed since the diagnosis of diabetes (diabetes duration at the moment of the second measurement of HbA~1c~) as well as information about the patient's chronic conditions necessary to score the cumulative illness rating scale (CIRS) ([@b22-dmso-1-033]; [@b10-dmso-1-033], [@b7-dmso-1-033], [@b8-dmso-1-033]). The three nurses, blinded to the objectives of the study, had received an half-day training in CIRS scoring prior to the study.

The CIRS is a measure of comorbidity that takes into account all medical conditions and includes the notion of severity ([@b22-dmso-1-033]; [@b10-dmso-1-033], [@b7-dmso-1-033], [@b8-dmso-1-033]). It has been validated in primary care as a tool for quantifying comorbidity ([@b16-dmso-1-033], [@b15-dmso-1-033]). The CIRS uses a scoring system that encompasses 14 anatomical domains (cardiac, vascular, hematological, respiratory, ophthalmologic--otorhinolaryngologic, upper gastrointestinal, lower gastrointestinal, hepatic--pancreatic, renal, genitourinary, musculoskeletal--tegument, neurological, endocrine--metabolic--breast, and psychiatric) and assigns a value from 0 (no condition in this domain) to 4 (extremely severe problem) to determine a severity score for each domain. In the case of multiple conditions affecting a particular domain, the highest score is given to the domain. The global score is the sum of each domain's score. To use the CIRS as a measure of comorbidity for diabetes, this disease was not included in the global score of each patient.

Study groups were defined with a categorical variable (controlled/uncontrolled diabetes). Diabetes was considered as controlled if the mean value of the two measurements of HbA~1c~ levels was less than 7%; mean values equal or greater than 7% were considered as uncontrolled diabetes ([@b12-dmso-1-033]; [@b2-dmso-1-033]).

Data analysis
-------------

The differences between patients with controlled and uncontrolled diabetes were tested using the *t-*test for continuous variables such as CIRS score, age and diabetes duration, and the Chi-square test for categorical variables like sex and diabetes-related complications. Then, variables with *P* \< 0.1 were used as covariables in a multivariable logistic regression model to measure the association between diabetes control (dependant variable) and the CIRS score (independent variable).

According to various studies, the percentage of patients controlling their diabetes varies from 33% to 55% ([@b38-dmso-1-033]; [@b25-dmso-1-033]; [@b32-dmso-1-033]). When we estimated the sample size, we used the worst case scenario and anticipated a 2-to-1 ratio when comparing subjects with uncontrolled diabetes to subjects with controlled diabetes. A total sample size of 75 subjects was needed in order to achieve 80% statistical power, to detect a difference of 4 points on the CIRS with a standard deviation of 5.64 (based on a previous study) ([@b9-dmso-1-033]), with a two-sided t-test at the 5% significance level (nQuery Advisor 6.01). We increased this sample size by 30% to account for possible missing data in the charts and to allow controlling for 2 to 3 variables in the logistic regression model (requiring at least 30 subjects in the smallest group).

Analyses were made with SPSS software (version 13.0; SPSS Inc., Chicago, IL) and a *P* value \< 0.05 was considered statistically significant.

Results
=======

Ninety-six charts were reviewed for this study. Patients' characteristics and the two groups of diabetic patients are presented in [Table 1](#t1-dmso-1-033){ref-type="table"}. Statistical results from the univariate analyses performed to measure the associations between diabetes control and the patients' characteristics are indicated in [Table 1](#t1-dmso-1-033){ref-type="table"}.

Diabetes control was not significantly related with the CIRS score, age, sex, or diabetes-related complications. Diabetes control was however significantly related to diabetes duration. A logistic regression model was thus used to measure the association between diabetes control and the CIRS, by including the diabetes duration as a covariable. The relation was still not significant (adjusted odds ratio = 0.889; 95% confidence interval: 0.736--1.074; *p* = 0.223).

Discussion
==========

The results of this study suggest that in patients with type 2 diabetes mellitus, the presence of comorbidity measured with the CIRS, is not related to glycemia control defined by HbA~1c~ levels. The finding that glycemia control is associated with diabetes duration is similar to that of previous reports ([@b20-dmso-1-033]; [@b31-dmso-1-033]; [@b33-dmso-1-033]; [@b13-dmso-1-033]; [@b24-dmso-1-033]; [@b34-dmso-1-033]; [@b35-dmso-1-033]).

To our knowledge, this is the first study that used the CIRS to measure comorbidity in order to assess the relationship between comorbidity and glycemia control in type 2 diabetic patients. The CIRS score takes into account all comorbidities as well as their severity, and provides a good assessment of other chronic diseases that may coexist with diabetes mellitus, being or not etiologically associated with it. Compared to our comorbidity measuring method, previous studies on a possible association between comorbidity condition and glycemia control included a limited number of diseases ([@b39-dmso-1-033]; [@b38-dmso-1-033]; [@b32-dmso-1-033]) or diseases associated to diabetes exclusively ([@b32-dmso-1-033]). In these studies, the presence of comorbidities was found to be related to glycemia control. Our finding that the presence of comorbidities is not associated with glycemia control supports the conclusion of another study which also used a more comprehensive measurement of comorbidity, the chronic disease score (CDS) ([@b6-dmso-1-033]).

It has been reported that depending on the type of comorbid condition they have, diabetic patients are more or less likely to achieve HbA~1c~ levels under 7% ([@b25-dmso-1-033]). Therefore, when HbA~1c~ less than 7% threshold is used as a performance measure for diabetes quality of care, assessment of an association between glycemia control and comorbidity may be influenced by the type of comorbid conditions. In fact, the likelihood of finding an association between poor glycemia control and comorbidity in patients with diabetes-related complications would be higher than in patients without this type of complications ([@b25-dmso-1-033]). However, our study suggests that the presence of multiple chronic conditions is not a factor limiting the achievement of a good control of glycemia, even after taking into account the severity of the coexistent diseases. It has been reported that services received by diabetic patients do not differ based on comorbid illness burden ([@b11-dmso-1-033]), however diabetic patients with elevated HbA~1c~ receive a closer attention in primary care encounters ([@b27-dmso-1-033]). Therefore, in the presence of multiple comorbid conditions, diabetic patients may receive better care. As a matter of fact, it has been reported that vulnerable elders with multiple chronic conditions, including diabetes, receive better overall quality of care ([@b26-dmso-1-033]), and that the quality of care improves as a patient's number of chronic conditions increases ([@b14-dmso-1-033]).

Limitations
-----------

It could have been preferable to use a mean value of all HbA~1c~ over two years rather than using only the most recent two HbA~1c~ measures. However, given data abstraction techniques, it was not feasible to utilize additional values. Since we performed a retrospective study, one limitation of our method is that different variables such as the time elapsed between the two measurements of HbA~1c~ could not be controlled. Furthermore, in our sample, 69% of the patients had a good glycemia control ([Table 1](#t1-dmso-1-033){ref-type="table"}), a higher proportion compared to that in other studies (33%--55%) ([@b38-dmso-1-033]; [@b25-dmso-1-033]; [@b32-dmso-1-033]). The fact that our institution is a teaching hospital with a FMU may have influenced the quality of care provided, and biased the results towards a better glycemia control. There is also the possibility that a number of patients with more severe diabetes are followed up in specialized clinics and were therefore underrepresented in our sample. Another limitation of the study is that the patients were recruited from only one setting and therefore extrapolation of our results to other settings is more difficult to make.

Lack of statistical power could be an issue in the assessment of the relationship between diabetes-related complications and glycemia control. Given that the proportion of complications is around 50% when diabetes is not controlled, the two group chi-square test at the 0.05 level had a 34% statistical power to detect an odds ratio of 0.5 with sample sizes of 30 (uncontrolled diabetes) and 66 (controlled diabetes) (nQuery Advisor 6.01).

Despite these limitations, our study is strengthened by the use of a comprehensive comorbidity index to measure comorbidity that takes into account disease severity, a random patients' selection and the mean of two HbA~1c~ measurements instead of a single measurement.

Conclusion
==========

Our study suggests that comorbidity, measured with an exhaustive index, is not a factor that prevents the achievement of a good glycemia control in patients with type 2 diabetes. Further studies are needed to extend these results to other settings and to evaluate the impact of different types of medical conditions on glycemia control.
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###### 

Comparison of patients with controlled or uncontrolled diabetes

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristic[\*](#tfn2-dmso-1-033){ref-type="table-fn"}**   **Controlled diabetes (HbA~1c~ \< 7%)**\             **Uncontrolled diabetes (HbA~1c~ ≥ 7%)**\            ***P***
                                                                  **(n = 66)**                                         **(n = 30)**                                         
  --------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  Males, n (%)                                                    30.0 (45.0)                                          17.0 (57.0)                                          0.340[†](#tfn3-dmso-1-033){ref-type="table-fn"}

  Age, years                                                      67.8 (10.6)                                          65.2 (12.4)                                          0.290[\*\*](#tfn4-dmso-1-033){ref-type="table-fn"}

  Diabetes duration, years                                        6.7 (4.5)                                            11.3 (7.0)                                           0.003[\*\*](#tfn4-dmso-1-033){ref-type="table-fn"}

                                                                  (n = 34)[§](#tfn6-dmso-1-033){ref-type="table-fn"}   (n = 23)[§](#tfn6-dmso-1-033){ref-type="table-fn"}   

  CIRS score                                                      9.0 (4.0)                                            8.9 (3.7)                                            0.850[\*\*](#tfn4-dmso-1-033){ref-type="table-fn"}

  HbA~1c~[\*\*\*](#tfn5-dmso-1-033){ref-type="table-fn"}, %       6.1 (0.4)                                            8.1 (1.2)                                            0.007[\*\*](#tfn4-dmso-1-033){ref-type="table-fn"}

  Diabetes-related complications, n (%)                           22.0 (33.0)                                          15.0 (50.0)                                          0.120[†](#tfn3-dmso-1-033){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Unless otherwise indicated, data are given as mean (SD);

*P*-value was based on Chi-square test;

*P*-value was based on *t*-test;

Average of two measurements;

Number of patients for whom information on diabetes duration was available.

**Abbreviations:** HbA~1c~, glycosylated hemoglobin; CIRS, cumulative illness rating scale.
